Shanghai RAAS Blood Products (002252.SZ): "SR604 Injection" enters Phase III clinical trials

Shanghai RAAS Blood Products (002252.SZ) announced that its investigational product "SR604 Injection" has recently been listed on the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform for a Phase III clinical trial registration for "preventive treatment of bleeding episodes in patients with hemophilia A/B." Trial name: A single-arm, multicenter Phase III clinical trial evaluating the efficacy and safety of SR604 Injection for preventive treatment in patients with hemophilia A/B with or without inhibitors. Trial objective: To evaluate the efficacy of SR604 Injection for preventive treatment in patients with hemophilia A/B with or without inhibitors. Based on prior exploration of multiple doses and dosing intervals of SR604 Injection in hemophilia A/B, the company is now conducting a Phase III confirmatory clinical study for the indication of preventive treatment of bleeding episodes in patients with hemophilia A/B, planning a multiple-dose trial of 0.4 mg/kg administered once every 4 weeks. If successfully developed, this product is expected to significantly improve the medication experience for patients with hemophilia A/B. As of the disclosure date of this announcement, no product with the same target as this drug has been approved globally.